Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective…
$TNGX Long Chart showing a good reversal as the market starts to focus on the next major catalyst: ESMO. Updated data on vopimetostat combinations could provide further clarity on durability, efficacy, and the path toward later-stage development. $RVMD Long
This Is a Good Time to Make a Stock-Picking List As biotech is getting hit and we’re seeing ETF-driven selling, I smell opportunity for sharp traders. $BBIO $BFLY $RVMD etc https://t.co/2aXZ1q0p1d
Something is going on in biotech today $IBB A lot of breakdowns $RVMD $TGTX $ABVX etc
Baron's cover - Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Some of the names mentioned include my baby $IMNM & $VRTX $RVMD $MRNA $ORKA
$RVMD nice retake of 50d MA and back into its @MarketWebs Sept Value Area https://t.co/myNd5hXuuf
23 analysts rate RVMD Buy on consensus.
Consensus price target: $257.53 (+37.21% upside from $187.69)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Sandler Alan B. Chief Development Officer | Sep 29, 2026 | Sale | 1,609 | $324.57K |
| Sandler Alan B. Chief Development Officer | Sep 29, 2026 | Sale | 301 | $61.62K |
| Sandler Alan B. Chief Development Officer | Sep 29, 2026 | Sale | 1,000 | $202.81K |
| Sandler Alan B. Chief Development Officer | Sep 29, 2026 | Sale | 2,200 | $441.8K |
| Sandler Alan B. Chief Development Officer | Sep 29, 2026 | Sale | 1,199 | $244.48K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-1.13B |
| 2024 | $0 | -100% | $-600.09M |
| 2023 | $11.58M | -67.27% | $-436.37M |
Stock data for RVMD: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics